Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb

Clement Morgat, Michiel Van de Voorde, S. Bodin, C. Champion, E. Hindié

Research outputpeer-review


161Tb has aroused great interest to improve response rate of targeted radionuclide therapy due to its unique decay features. In this review article, decay properties of medically relevant radionuclides of the terbium element are first described. Next, modeling studies, production, preclinical and clinical studies performed using 161Tb in prostate cancer are reviewed.
Original languageFrench
Pages (from-to)333-338
Number of pages6
JournalMédecine Nucléaire
Issue number6
Early online date5 Oct 2023
StatePublished - Nov 2023

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this